Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Evidence that the Ciliary Inhibitor of Cystic Fibrosis is not an Antibody
Victoria Herzberg, Lynette Calvert, Barbara H. Bowman
Victoria Herzberg, Lynette Calvert, Barbara H. Bowman
View: Text | PDF
Research Article

Evidence that the Ciliary Inhibitor of Cystic Fibrosis is not an Antibody

  • Text
  • PDF
Abstract

An inhibitor of ciliary activity is present in the serum of cystic fibrosis (CF) patients and heterozygotes. Fractionation of CF serum has indicated that the inhibitor is associated with the serum IgG fraction. This study compared the activity of the CF inhibitor to that of rabbit antibody preparations directed against oyster cilia. The aim of this investigation was to determine whether the ciliary inhibitory mechanism in cystic fibrosis is related to a typical immunological reaction. Results from experiments utilizing fluorescent antibody techniques demonstrated that an antiserum directed against oyster ciliated epithelium binds immunologically with both human bronchial and oyster epithelial tissue. Results from experiments utilizing immunofluorescent tracing, passive hemagglutination, double immunodiffusion, and papain digestion, however, indicated that the interaction between the oyster cilia and the CF serum inhibitor was not a typical antigen-antibody reaction.

Authors

Victoria Herzberg, Lynette Calvert, Barbara H. Bowman

×

Full Text PDF


Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts